{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:25:44Z","timestamp":1791203144415,"version":"4.2.0"},"reference-count":363,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"DOI":"10.3389\/fpsyt.2019.00605","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T10:41:58Z","timestamp":1567593718000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":77,"title":["Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders"],"prefix":"10.3389","volume":"10","author":[{"given":"Rickinder","family":"Sethi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"G\u00f3mez-Coronado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D\u2019Arcy","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Agustini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seetal","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12698","article-title":"Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies","volume":"135","author":"Kohler","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"B2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1741-7015-11-200","article-title":"So depression is an inflammatory disease, but where does the inflammation come from","volume":"11","author":"Berk","year":"2013","journal-title":"BMC Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.v10n0201","article-title":"What are the implications of the STAR*D trial for primary care? A review and synthesis","volume":"10","author":"Huynh","year":"2008","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001805","article-title":"The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine","volume":"11","author":"Muller","year":"2006","journal-title":"Mol Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/da.20589","article-title":"Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial","volume":"26","author":"Akhondzadeh","year":"2009","journal-title":"Depress Anxiety"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e318227f4da","article-title":"Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial","volume":"20","author":"Fields","year":"2012","journal-title":"Am J Geriatr Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.03.033","article-title":"Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study","volume":"141","author":"Abbasi","year":"2012","journal-title":"J Affect Disord"},{"key":"B8","article-title":"A randomized, double-blind, placebo-controlled trial of celecoxib uugmentation of sertraline in treatment of drug-naive depressed women: a pilot study","volume":"14","author":"Majd","year":"2015","journal-title":"IJPR"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12287","article-title":"Celecoxib for the treatment of mild-to-moderate depression due to acute brucellosis: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Jafari","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015592215","article-title":"Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double-blind, placebo-controlled, randomized trial","volume":"49","author":"Mohammadinejad","year":"2015","journal-title":"Ann Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.psychres.2017.05.029","article-title":"Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: a randomized double-blind, placebo controlled trial","volume":"255","author":"Alamdarsaravi","year":"2017","journal-title":"Psychiatry Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/hup.912","article-title":"Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Nery","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1559667","article-title":"Effect of adjunctive celecoxib on BDNF in manic patients undergoing electroconvulsive therapy: a randomized double blind controlled trial","volume":"48","author":"Kargar","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12324","article-title":"Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Arabzadeh","year":"2015","journal-title":"Bipolar Disord"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1549929","article-title":"Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: a double-blind, placebo-controlled, randomized trial","volume":"48","author":"Shalbafan","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2011.01.019","article-title":"A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder","volume":"189","author":"Sayyah","year":"2011","journal-title":"Psychiatry Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.1029","article-title":"Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia","volume":"159","author":"Muller","year":"2002","journal-title":"Am J Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.02.024","article-title":"Celecoxib augmentation of continuously ill patients with schizophrenia","volume":"57","author":"Rapaport","year":"2005","journal-title":"Biol Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"M\u00fcller","year":"2010","journal-title":"Schizophr Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-012-2796-8","article-title":"Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"225","author":"Asadabadi","year":"2013","journal-title":"Psychopharmacology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-1934","article-title":"Hot brains: manipulating body heat to save the brain","volume":"117","author":"Raju","year":"2006","journal-title":"Pediatrics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788168001","article-title":"Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today","volume":"15","author":"Lopez-Munoz","year":"2009","journal-title":"Curr Pharm Des"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.12.980","article-title":"Overview of the immune response","volume":"125","author":"Chaplin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20143085","DOI":"10.1098\/rspb.2014.3085","article-title":"Evolution of the immune system in humans from infancy to old age","volume":"282","author":"Simon","year":"2015","journal-title":"Proc R Soc B: Biol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.imlet.2014.03.006","article-title":"Macrophages: a double-edged sword in experimental autoimmune encephalomyelitis","volume":"160","author":"Jiang","year":"2014","journal-title":"Immunol Lett"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.98","article-title":"Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target","volume":"12","author":"McNamara","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.5.683","article-title":"Cytokines and the brain: implications for clinical psychiatry","volume":"157","author":"Kronfol","year":"2000","journal-title":"Am J Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1159\/000097202","article-title":"Passage of cytokines across the blood-brain barrier","volume":"2","author":"Banks","year":"1995","journal-title":"Neuroimmunomodulation"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00350-3","article-title":"Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide","volume":"83","author":"Quan","year":"1998","journal-title":"Neuroscience"},{"key":"B31","doi-asserted-by":"publisher","first-page":"92448","DOI":"10.1177\/0004867418796955","article-title":"Leaky brain in neurological and psychiatric disorders: drivers and consequences","volume":"52","author":"Morris","year":"2018","journal-title":"Aust N Z J Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.205","article-title":"Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior","volume":"37","author":"Haroon","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresrev.2010.09.008","article-title":"Neuroinflammation and brain infections: historical context and current perspectives","volume":"66","author":"Bentivoglio","year":"2011","journal-title":"Brain Res Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrn2038","article-title":"Microglia-mediated neurotoxicity: uncovering the molecular mechanisms","volume":"8","author":"Block","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04505","article-title":"Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature","volume":"70","author":"Goldstein","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1742-2094-10-43","article-title":"Neuroinflammation and psychiatric illness","volume":"10","author":"Najjar","year":"2013","journal-title":"J Neuroinflammation"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13139","article-title":"Microglial M1\/M2 polarization and metabolic states","volume":"173","author":"Orihuela","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.tins.2005.12.005","article-title":"Microglial phenotype: is the commitment reversible","volume":"29","author":"Schwartz","year":"2006","journal-title":"Trends Neurosci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1075","DOI":"10.1038\/tp.2017.4","article-title":"Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies","volume":"7","author":"van Kesteren","year":"2017","journal-title":"Transl Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1742-2094-11-98","article-title":"Neuroinflammation and M2 microglia: the good, the bad, and the inflamed","volume":"11","author":"Cherry","year":"2014","journal-title":"J Neuroinflammation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2015.09.016","article-title":"Microglia activation is associated with IFN-alpha induced depressive-like behavior","volume":"55","author":"Wachholz","year":"2016","journal-title":"Brain Behav Immun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016303","article-title":"The chemokine system in innate immunity","volume":"7","author":"Sokol","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X14666151208113700","article-title":"Inflammation in depression and the potential for anti-inflammatory treatment","volume":"14","author":"Kohler","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2017.02.020","article-title":"Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression","volume":"62","author":"Kohler-Forsberg","year":"2017","journal-title":"Brain Behav Immun"},{"key":"B45","doi-asserted-by":"publisher","first-page":"26105","DOI":"10.1038\/srep26105","article-title":"A significant causal association between C-reactive protein levels and schizophrenia","volume":"6","author":"Inoshita","year":"2016","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamapsychiatry.102","article-title":"Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals","volume":"70","author":"Wium-Andersen","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.2.237","article-title":"C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992","volume":"99","author":"Koenig","year":"1999","journal-title":"Circulation"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200010193431602","article-title":"Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease","volume":"343","author":"Lindahl","year":"2000","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.17.6.1121","article-title":"Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project","volume":"17","author":"Tracy","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2013.08.014","article-title":"The association between depressive symptoms, cognitive function, and inflammation in major depression","volume":"35","author":"Krogh","year":"2014","journal-title":"Brain Behav Immun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.psychres.2015.06.009","article-title":"Examining the role of neuroinflammation in major depression","volume":"229","author":"Furtado","year":"2015","journal-title":"Psychiatry Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.psychres.2011.12.007","article-title":"Serum concentrations of CRP, IL-6, TNF-alpha and cortisol in major depressive disorder with melancholic or atypical features","volume":"198","author":"Karlovic","year":"2012","journal-title":"Psychiatry Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.neuroscience.2013.04.060","article-title":"Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications","volume":"246","author":"Felger","year":"2013","journal-title":"Neuroscience"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2016.3","article-title":"A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression","volume":"21","author":"Goldsmith","year":"2016","journal-title":"Mol Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.biopsych.2013.01.007","article-title":"Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies","volume":"74","author":"Modabbernia","year":"2013","journal-title":"Biol Psychiatry"},{"key":"B60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jad.2012.06.010","article-title":"Cytokines in bipolar disorder: a systematic review and meta-analysis","volume":"144","author":"Munkholm","year":"2013","journal-title":"J Affect Disord"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol Psychiatry"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-012-0272-0","article-title":"Systematic review of proinflammatory cytokines in obsessive-compulsive disorder","volume":"14","author":"Gray","year":"2012","journal-title":"Curr Psychiatry Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.59","article-title":"Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis","volume":"20","author":"Masi","year":"2015","journal-title":"Mol Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.132","article-title":"The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis","volume":"36","author":"Hannestad","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119846","article-title":"Pathways and mechanisms for cytokine signaling of the central nervous system","volume":"100","author":"Licinio","year":"1997","journal-title":"J Clin Invest"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2008.12.001","article-title":"Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder","volume":"116","author":"Brietzke","year":"2009","journal-title":"J Affect Disord"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2009.04.002","article-title":"Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients","volume":"43","author":"de Oliveira","year":"2009","journal-title":"J Psychiatr Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12916-015-0529-7","article-title":"Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies","volume":"13","author":"Fernandes","year":"2015","journal-title":"BMC Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2013.172","article-title":"Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis","volume":"19","author":"Fernandes","year":"2014","journal-title":"Mol Psychiatry"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.117","article-title":"Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications","volume":"20","author":"Fernandes","year":"2015","journal-title":"Mol Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.2174\/157339510791823835","article-title":"The concept of depression as a dysfunction of the immune system","volume":"6","author":"Leonard","year":"2010","journal-title":"Curr Immunol Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/mpr.138","article-title":"The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys","volume":"12","author":"Andrade","year":"2003","journal-title":"Int J Methods Psychiatr Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2004.10.003","article-title":"Acute inflammation and negative mood: mediation by cytokine activation","volume":"19","author":"Wright","year":"2005","journal-title":"Brain Behav Immun"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002148","article-title":"\u2018Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice","volume":"14","author":"O\u2019Connor","year":"2009","journal-title":"Mol Psychiatry"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.5.445","article-title":"Cytokine-associated emotional and cognitive disturbances in humans","volume":"58","author":"Reichenberg","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.11.017","article-title":"Depression, cytokines and experimental pain: evidence for sex-related association patterns","volume":"131","author":"Euteneuer","year":"2010","journal-title":"J Affect Disord"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2008.09.007","article-title":"Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans","volume":"23","author":"Brydon","year":"2009","journal-title":"Brain Behav Immun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2005.04.019","article-title":"Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice","volume":"81","author":"Dunn","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1213651","article-title":"Current and future therapies for hepatitis C virus infection","volume":"368","author":"Liang","year":"2013","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.51.6.466","article-title":"Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma","volume":"51","author":"Friebe","year":"2010","journal-title":"Psychosomatics"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000192087.64432.ae","article-title":"Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study","volume":"19","author":"Reichenberg","year":"2005","journal-title":"Aids"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12r07694","article-title":"Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis","volume":"73","author":"Udina","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028330","article-title":"Dose-dependent effects of endotoxin on neurobehavioral functions in humans","volume":"6","author":"Grigoleit","year":"2011","journal-title":"PLoS One"},{"key":"B86","doi-asserted-by":"publisher","first-page":"65704","DOI":"10.1155\/2007\/65704","article-title":"Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder","volume":"2007","author":"Konuk","year":"2007","journal-title":"Mediators Inflamm"},{"key":"B87","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/00006842-200201000-00008","article-title":"Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis","volume":"64","author":"Dickens","year":"2002","journal-title":"Psychosom Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2240-3","article-title":"Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link","volume":"54","author":"Korczak","year":"2011","journal-title":"Diabetologia"},{"key":"B89","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12888-017-1234-1","article-title":"Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Psychiatry"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.1111","article-title":"Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study","volume":"70","author":"Benros","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1023\/B:DDAS.0000020509.23162.cc","article-title":"Crohn\u2019s disease: a two-year prospective study of the association between psychological distress and disease activity","volume":"49","author":"Mardini","year":"2004","journal-title":"Dig Dis Sci"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.09.014","article-title":"Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"63","author":"Langley","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.022","article-title":"The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial","volume":"62","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717740344","article-title":"Bipolar disorder associated with another autoimmune disease-pemphigus: a population-based study","volume":"63","author":"Kridin","year":"2017","journal-title":"Can J Psychiatry"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.11030516","article-title":"Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study","volume":"168","author":"Benros","year":"2011","journal-title":"Am J Psychiatry"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117620","article-title":"Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction","volume":"94","author":"Harris","year":"1994","journal-title":"J Clin Invest"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.2.517","article-title":"Prostaglandin endoperoxide-H synthase-1 and -2 messenger ribonucleic acid levels in human amnion with spontaneous labor onset","volume":"80","author":"Hirst","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069524","article-title":"LC-MS\/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression","volume":"8","author":"Kirkby","year":"2013","journal-title":"PLoS One"},{"key":"B100","doi-asserted-by":"publisher","first-page":"7908","DOI":"10.1038\/sj.onc.1203286","article-title":"The role of cyclooxygenases in inflammation, cancer, and development","volume":"18","author":"Williams","year":"1999","journal-title":"Oncogene"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1992.263.1.F97","article-title":"Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids","volume":"263","author":"Coyne","year":"1992","journal-title":"Am J Physiol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90396-7","article-title":"PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs","volume":"95","author":"DeWitt","year":"1993","journal-title":"Am J Med"},{"key":"B103","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(17)44821-6","article-title":"The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes","volume":"265","author":"Fu","year":"1990","journal-title":"J Biol Chem"},{"key":"B104","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4049\/jimmunol.155.2.796","article-title":"Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes","volume":"155","author":"Geng","year":"1995","journal-title":"J Immunol"},{"key":"B105","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(18)52976-8","article-title":"Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines","volume":"268","author":"Jones","year":"1993","journal-title":"J Biol Chem"},{"key":"B106","article-title":"Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide","volume":"267","author":"Lee","year":"1992","journal-title":"J Biol Chem"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(92)91313-F","article-title":"Lipopolysaccharide induces prostaglandin H synthase-2 in alveolar macrophages","volume":"187","author":"O\u2019Sullivan","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.55.4.476","article-title":"Transient expression of prostaglandin endoperoxide synthase-2 during mouse macrophage activation","volume":"55","author":"Riese","year":"1994","journal-title":"J Leukoc Biol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-012-9326-6","article-title":"Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression","volume":"27","author":"Maes","year":"2012","journal-title":"Metab Brain Dis"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1097\/nen.0b013e3180517477","article-title":"Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration","volume":"66","author":"Minghetti","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00025-1","article-title":"The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression","volume":"49","author":"Song","year":"1998","journal-title":"J Affect Disord"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1021\/cn500058v","article-title":"Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade","volume":"5","author":"Rapoport","year":"2014","journal-title":"ACS Chem Neurosci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M001387200","article-title":"Feedback control of cyclooxygenase-2 expression through PPARgamma","volume":"275","author":"Inoue","year":"2000","journal-title":"J Biol Chem"},{"key":"B114","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mce.2008.01.016","article-title":"Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element","volume":"285","author":"Sales","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"B115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.31887\/DCNS.2017.19.1\/nmueller","article-title":"Immunological aspects of the treatment of depression and schizophrenia","volume":"19","author":"M\u00fcller","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.03926.x","article-title":"Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis","volume":"98","author":"Choi","year":"2006","journal-title":"J Neurochem"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbrainres.2005.05.008","article-title":"Down-regulation of brain nuclear factor-kappa B pathway in the cyclooxygenase-2 knockout mouse","volume":"139","author":"Rao","year":"2005","journal-title":"Brain Res Mol Brain Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1136\/gut.2005.065003","article-title":"COX-2 chronology","volume":"54","author":"Hawkey","year":"2005","journal-title":"Gut"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16894-3","article-title":"\u2018Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial","volume":"364","author":"Farkouh","year":"2004","journal-title":"Lancet"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"B124","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12916-015-0285-8","article-title":"Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis\u2014an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks","volume":"13","author":"Scarpignato","year":"2015","journal-title":"BMC Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000287","article-title":"Effect of rofecoxib on nociception and the serotonin system in the rat brain","volume":"51","author":"Sandrini","year":"2002","journal-title":"Inflamm Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2012.06.003","article-title":"Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat","volume":"39","author":"Johansson","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2009.01.002","article-title":"The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research","volume":"30","author":"Choi","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(07)82014-9","article-title":"Cyclooxygenase-2, prostaglandin E2, and microglial activation in prion diseases","volume":"82","author":"Minghetti","year":"2007","journal-title":"Int Rev Neurobiol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-364-6_15","article-title":"In vivo models to study cyclooxygenase products in health and disease: introduction to part III","volume":"644","author":"Gilroy","year":"2010","journal-title":"Methods Mol Biol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/378406a0","article-title":"Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II","volume":"378","author":"Dinchuk","year":"1995","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90125-6","article-title":"Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse","volume":"83","author":"Morham","year":"1995","journal-title":"Cell"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2009.223","article-title":"Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood\u2013brain barrier disruption through matrix metalloproteinase activity","volume":"30","author":"Aid","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"key":"B133","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/9550","article-title":"Inducible cyclooxygenase may have anti-inflammatory properties","volume":"5","author":"Gilroy","year":"1999","journal-title":"Nat Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(03)00179-6","article-title":"Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils","volume":"3","author":"Kimura","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1089\/089771502753754091","article-title":"Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death","volume":"19","author":"Strauss","year":"2002","journal-title":"J Neurotrauma"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(00)00137-6","article-title":"Different hippocampal molecular requirements for short- and long-term retrieval of one-trial avoidance learning","volume":"111","author":"Izquierdo","year":"2000","journal-title":"Behav Brain Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0197-0186(00)00101-7","article-title":"Kainate-induced genes in the hippocampus: lessons from expression patterns","volume":"38","author":"Zagulska-Szymczak","year":"2001","journal-title":"Neurochem Int"},{"key":"B138","doi-asserted-by":"publisher","first-page":"457079","DOI":"10.1155\/2011\/457079","article-title":"Kainic acid-induced neurodegenerative model: potentials and limitations","volume":"2011","author":"Zheng","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1124\/jpet.302.3.846","article-title":"Pharmacology of celecoxib in rat brain after kainate administration","volume":"302","author":"Ciceri","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.5607\/en.2009.18.1.13","article-title":"Celecoxib attenuates kainic acid-induced neuronal cell death through suppression of microglial c-Jun N-terminal kinase phosphorylation","volume":"18","author":"Byun","year":"2009","journal-title":"Exp Neurobiol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)01797-7","article-title":"Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus","volume":"843","author":"Baik","year":"1999","journal-title":"Brain Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-08-02746.1997","article-title":"Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage","volume":"17","author":"Nogawa","year":"1997","journal-title":"J Neurosci"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804852105","article-title":"S-nitrosylation\/activation of COX-2 mediates NMDA neurotoxicity","volume":"105","author":"Tian","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B144","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3389\/fncel.2014.00430","article-title":"Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity","volume":"8","author":"Calabrese","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"B145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fncel.2014.00419","article-title":"The neuroimmune-neuroplasticity interface and brain pathology","volume":"8","author":"Hayley","year":"2014","journal-title":"Front Cell Neurosci"},{"key":"B146","first-page":"1","article-title":"Putative neuroprotective pharmacotherapies to target the staged progression of mental illness","volume-title":"Early Intervention in Psychiatry","author":"Robertson","year":"2019"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.01.014","article-title":"Immune system to brain signaling: neuropsychopharmacological implications","volume":"130","author":"Capuron","year":"2011","journal-title":"Pharmacol Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/da.22084","article-title":"Cytokine targets in the brain: impact on neurotransmitters and neurocircuits","volume":"30","author":"Miller","year":"2013","journal-title":"Depress Anxiety"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5952-4_32","article-title":"Tryptophan nutrition and metabolism: an overview","volume":"294","author":"Peters","year":"1991","journal-title":"Adv Exp Med Biol"},{"key":"B150","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61","author":"Hirschfeld","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"B151","article-title":"The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression","volume":"29","author":"Maes","year":"2008","journal-title":"Neuro Endocrinol Lett"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(98)00016-3","article-title":"Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism","volume":"33","author":"Wang","year":"1998","journal-title":"Neurochem Int"},{"key":"B153","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/mp.2009.116","article-title":"CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression","volume":"15","author":"Raison","year":"2010","journal-title":"Mol Psychiatry"},{"key":"B154","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1742-2094-8-94","article-title":"Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission","volume":"8","author":"Steiner","year":"2011","journal-title":"J Neuroinflammation"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/nrd870","article-title":"Endogenous kynurenines as targets for drug discovery and development","volume":"1","author":"Stone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.09.006","article-title":"An expanding range of targets for kynurenine metabolites of tryptophan","volume":"34","author":"Stone","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington\u2019s disease striatum: evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J Neurochem"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2007.01.010","article-title":"Depressive disorders and immunity: 20 years of progress and discovery","volume":"21","author":"Irwin","year":"2007","journal-title":"Brain Behav Immun"},{"key":"B159","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1155\/2013\/104024","article-title":"Quinolinic acid: an endogenous neurotoxin with multiple targets","volume":"2013","author":"Lugo-Huitr\u00f3n","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.140","article-title":"Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression","volume":"38","author":"Miller","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2003.10.006","article-title":"\u2018The kynurenine pathway of tryptophan degradation as a drug target","volume":"4","author":"Schwarcz","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c150015","article-title":"Regulation of the hypothalamic\u2013pituitary\u2013adrenocortical stress response","volume":"6","author":"Herman","year":"2016","journal-title":"Compr Physiol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2009.07.012","article-title":"The impact of treatment on HPA axis activity in unipolar major depression","volume":"44","author":"McKay","year":"2010","journal-title":"J Psychiatr Res"},{"key":"B164","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1179\/096805103125001298","article-title":"Endotoxin and the hypothalamo\u2013pituitary\u2013adrenal (HPA) axis","volume":"9","author":"Beishuizen","year":"2003","journal-title":"J Endotoxin Res"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb05426.x","article-title":"Cytokine activation of the HPA axis","volume":"917","author":"Dunn","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"B166","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/vim.2005.18.41","article-title":"Immune modulation of the hypothalamic\u2013pituitary\u2013adrenal (HPA) axis during viral infection","volume":"18","author":"Silverman","year":"2005","journal-title":"Viral Immunol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1749-6632.2012.06633.x","article-title":"Glucocorticoid regulation of inflammation and its behavioral and metabolic correlates: from HPA axis to glucocorticoid receptor dysfunction","volume":"1261","author":"Silverman","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B168","first-page":"56","article-title":"Tryptophan\u2013kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later","volume":"47","author":"Oxenkrug","year":"2010","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"B169","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pnpbp.2014.01.013","article-title":"\u2018Inflamed moods: a review of the interactions between inflammation and mood disorders","volume":"53","author":"Rosenblat","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.177.5.390","article-title":"Future therapeutic targets in mood disorders: the glucocorticoid receptor","volume":"177","author":"McQuade","year":"2000","journal-title":"Br J Psychiatry"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1554","article-title":"When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders","volume":"160","author":"Raison","year":"2003","journal-title":"Am J Psychiatry"},{"key":"B172","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1677\/JOE-08-0509","article-title":"Acute or chronic stress induce cell compartment-specific phosphorylation of glucocorticoid receptor and alter its transcriptional activity in Wistar rat brain","volume":"202","author":"Adzic","year":"2009","journal-title":"J Endocrinol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2010.03.007","article-title":"The glucocorticoid receptor: pivot of depression and of antidepressant treatment","volume":"36","author":"Anacker","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04978.x","article-title":"Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids","volume":"1179","author":"Pariante","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2009.01981.x","article-title":"Smaller pituitary volume in adult patients with obsessive-compulsive disorder","volume":"63","author":"Atmaca","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"key":"B176","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jad.2014.08.022","article-title":"\u2018Pituitary gland volumes in bipolar disorder","volume":"169","author":"Clark","year":"2014","journal-title":"J Affect Disord"},{"key":"B177","first-page":"5","article-title":"The neurobiology of depression: inroads to treatment and new drug discovery","volume":"66","author":"Nemeroff","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2013.06.030","article-title":"Pituitary gland volume in patients with schizophrenia, subjects at ultra high-risk of developing psychosis and healthy controls: a systematic review and meta-analysis","volume":"38","author":"Nordholm","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2005.08.014","article-title":"Th2 cytokine response in major depressive disorder patients before treatment","volume":"172","author":"Pavon","year":"2006","journal-title":"J Neuroimmunol"},{"key":"B180","article-title":"HPA axis function as biomarker for atypical and melancholic depression","volume-title":"Front Psychiatry","author":"Bocharova","year":"2019"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.144","article-title":"Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression","volume":"18","author":"Lamers","year":"2013","journal-title":"Mol Psychiatry"},{"key":"B182","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.psyneuen.2014.07.013","article-title":"Morning cortisol levels in schizophrenia and bipolar disorder: a meta-analysis","volume":"49","author":"Girshkin","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6260","article-title":"Inflammatory neuroprotection following traumatic brain injury","volume":"353","author":"Russo","year":"2016","journal-title":"Science"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202529","article-title":"Synaptic pruning by microglia is necessary for normal brain development","volume":"333","author":"Paolicelli","year":"2011","journal-title":"Science"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(94)90009-4","article-title":"Is Schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited","volume":"28","author":"Keshavan","year":"1994","journal-title":"J Psychiatr Res"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/mp.2016.103","article-title":"Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects","volume":"22","author":"Kim","year":"2016","journal-title":"Mol Psychiatry"},{"key":"B187","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/YCO.0b013e32835aa4b4","article-title":"Is bipolar disorder an inflammatory condition? The relevance of microglial activation","volume":"26","author":"Stertz","year":"2013","journal-title":"Curr Opin Psychiatry"},{"key":"B188","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fphar.2012.00041","article-title":"Microglial activation\u2014tuning and pruning adult neurogenesis","volume":"3","author":"Ekdahl","year":"2012","journal-title":"Front Pharmacol"},{"key":"B189","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.3390\/ijerph8072980","article-title":"Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity","volume":"8","author":"Kraft","year":"2011","journal-title":"Int J Environ Res Public Health"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610212000828","article-title":"The role of glia in late-life depression","volume":"24","author":"Paradise","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2010.01.010","article-title":"Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction","volume":"22","author":"Park","year":"2010","journal-title":"Cell Signal"},{"key":"B192","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1176\/appi.ajp.2015.14101358","article-title":"Microglial activity in people at ultra high risk of psychosis and in schizophrenia; an [(11)C]PBR28 PET brain imaging study","volume":"173","author":"Bloomfield","year":"2016","journal-title":"Am J Psychiatry"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13364","article-title":"Microglial activation and progressive brain changes in schizophrenia","volume":"173","author":"Laskaris","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/mp.2016.90","article-title":"Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review","volume":"21","author":"Tr\u00e9panier","year":"2016","journal-title":"Mol Psychiatry"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400716","article-title":"Ontogeny and functions of central nervous system macrophages","volume":"193","author":"Katsumoto","year":"2014","journal-title":"J Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58644","article-title":"Innate immunity in the central nervous system","volume":"122","author":"Ransohoff","year":"2012","journal-title":"J Clin Invest"},{"key":"B197","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jad.2011.03.049","article-title":"Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies","volume":"138","author":"Bora","year":"2012","journal-title":"J Affect Disord"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.01.020","article-title":"Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder","volume":"67","author":"Bora","year":"2010","journal-title":"Biol Psychiatry"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291711001668","article-title":"Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder","volume":"42","author":"Bora","year":"2012","journal-title":"Psychol Med"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2206","article-title":"Identification of a common neurobiological substrate for mental illness","volume":"72","author":"Goodkind","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.05.020","article-title":"Midline brain structures in patients with current and remitted major depression","volume":"33","author":"Takahashi","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2012.11.007","article-title":"Putative neuroprotective agents in neuropsychiatric disorders","volume":"42","author":"Dodd","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B203","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/archgenpsychiatry.2010.180","article-title":"Development of lifetime comorbidity in the World Health Organization world mental health surveys","volume":"68","author":"Kessler","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Biol Psychiatry"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0b013e3181907c1b","article-title":"Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis","volume":"71","author":"Howren","year":"2009","journal-title":"Psychosom Med"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(99)00134-7","article-title":"Cytokine production and treatment response in major depressive disorder","volume":"22","author":"Lanquillon","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2006.05.013","article-title":"Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy","volume":"41","author":"O\u2019Brien","year":"2007","journal-title":"J Psychiatr Res"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.1332","article-title":"Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study","volume":"71","author":"Khandaker","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.256","article-title":"The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods","volume":"17","author":"Penninx","year":"2008","journal-title":"Int J Methods Psychiatr Res"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2015.02.007","article-title":"Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder","volume":"46","author":"Savitz","year":"2015","journal-title":"Brain Behav Immun"},{"key":"B211","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fpsyt.2017.00016","article-title":"High kynurenine (a tryptophan metabolite) predicts remission in patients with major depression to add-on treatment with celecoxib","volume":"8","author":"Krause","year":"2017","journal-title":"Front Psychiatry"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.01.016","article-title":"The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder","volume":"138","author":"Ga\u0142ecki","year":"2012","journal-title":"J Affect Disord"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31818ac2f7","article-title":"The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells","volume":"32","author":"Lee","year":"2009","journal-title":"J Immunother"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.11.029","article-title":"Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression","volume":"65","author":"Miller","year":"2009","journal-title":"Biol Psychiatry"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001644","article-title":"Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function","volume":"10","author":"Hu","year":"2005","journal-title":"Mol Psychiatry"},{"key":"B216","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1523\/JNEUROSCI.3569-08.2009","article-title":"Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment","volume":"29","author":"Song","year":"2009","journal-title":"J Neurosci"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1980.tb08725.x","article-title":"Regulation of noradrenaline overflow in rat cerebral cortex by prostaglandin E2","volume":"70","author":"Hillier","year":"1980","journal-title":"Br J Pharmacol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10192","article-title":"Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat","volume":"68","author":"Casolini","year":"2002","journal-title":"J Neurosci Res"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(00)02088-9","article-title":"Cytokine-induced sickness behaviour: mechanisms and implications","volume":"25","author":"Konsman","year":"2002","journal-title":"Trends Neurosci"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2004.11.003","article-title":"Cytokines and major depression","volume":"29","author":"Schiepers","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2006.07.013","article-title":"Kynurenine pathway in major depression: evidence of impaired neuroprotection","volume":"98","author":"Myint","year":"2007","journal-title":"J Affect Disord"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200607000-00004","article-title":"Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression","volume":"21","author":"Brunello","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.1611","article-title":"Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials","volume":"71","author":"Kohler","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"B224","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pnpbp.2013.09.006","article-title":"Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis","volume":"48","author":"Na","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B225","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pnpbp.2016.02.006","article-title":"A meta-analysis of chemokines in major depression","volume":"68","author":"Eyre","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.4306\/pi.2008.5.4.232","article-title":"Standardization of the Korean version of the Geriatric Depression Scale: reliability, validity, and factor structure","volume":"5","author":"Kim","year":"2008","journal-title":"Psychiatry Investig"},{"key":"B227","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1574891X11308010005","article-title":"Immunopathology of Brucella infection","volume":"8","author":"Baldi","year":"2013","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.20506\/rst.32.1.2192","article-title":"Pathogenesis and pathobiology of zoonotic brucellosis in humans","volume":"32","author":"Baldi","year":"2013","journal-title":"Rev Sci Tech"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.02.037","article-title":"NSAIDs are associated with lower depression scores in patients with osteoarthritis","volume":"126","author":"Iyengar","year":"2013","journal-title":"Am J Med"},{"key":"B230","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/hed.20662","article-title":"Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract","volume":"30","author":"Lai","year":"2008","journal-title":"Head Neck"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.24.3.505","article-title":"Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia","volume":"24","author":"Lundholm","year":"2004","journal-title":"Int J Oncol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.16","article-title":"A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders","volume":"71","author":"Pedersen","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00324.x","article-title":"Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia","volume":"9","author":"Malhi","year":"2007","journal-title":"Bipolar Disord"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2015.06.026","article-title":"Impaired conflict resolution and vigilance in euthymic bipolar disorder","volume":"229","author":"Marotta","year":"2015","journal-title":"Psychiatry Res"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-014-0887-z","article-title":"Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors","volume":"49","author":"Baumeister","year":"2014","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000799","article-title":"Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients","volume":"13","author":"Drexhage","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14r09007","article-title":"C-reactive protein alterations in bipolar disorder: a meta-analysis","volume":"76","author":"Dargel","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.05.018","article-title":"\u2018Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis","volume":"47","author":"Munkholm","year":"2013","journal-title":"J Psychiatr Res"},{"key":"B239","doi-asserted-by":"publisher","first-page":"360481","DOI":"10.1155\/2014\/360481","article-title":"Cytokines in bipolar disorder: paving the way for neuroprogression","volume":"2014","author":"Barbosa","year":"2014","journal-title":"Neural Plast"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1159\/000356539","article-title":"The immunology of bipolar disorder","volume":"21","author":"Barbosa","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2014.03.016","article-title":"Neuroinflammation in bipolar disorder - A [(11)C]-(R)-PK11195 positron emission tomography study","volume":"40","author":"Haarman","year":"2014","journal-title":"Brain Behav Immun"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.140183","article-title":"Monocyte and microglial activation in patients with mood-stabilized bipolar disorder","volume":"40","author":"Jakobsson","year":"2015","journal-title":"J Psychiatry Neurosci"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2009.47","article-title":"Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients","volume":"15","author":"Rao","year":"2010","journal-title":"Mol Psychiatry"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2012.01024.x","article-title":"Neuroprogression in bipolar disorder","volume":"14","author":"Schneider","year":"2012","journal-title":"Bipolar Disord"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2012.01022.x","article-title":"The functional neuroanatomy of bipolar disorder: a consensus model","volume":"14","author":"Strakowski","year":"2012","journal-title":"Bipolar Disord"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.01.007","article-title":"Cytokine production in bipolar affective disorder patients under lithium treatment","volume":"82","author":"Boufidou","year":"2004","journal-title":"J Affect Disord"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M002469","article-title":"Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation","volume":"51","author":"Basselin","year":"2010","journal-title":"J Lipid Res"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01452-X","article-title":"High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder","volume":"53","author":"Breunis","year":"2003","journal-title":"Biol Psychiatry"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005512","article-title":"Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder","volume":"65","author":"Chiu","year":"2013","journal-title":"Pharmacol Rev"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2007.00444.x","article-title":"An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment","volume":"9","author":"Knijff","year":"2007","journal-title":"Bipolar Disord"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1016\/j.plefa.2007.10.018","article-title":"Antimanic therapies target brain arachidonic acid signaling: lessons learned about the regulation of brain fatty acid metabolism","volume":"77","author":"Lee","year":"2007","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.11.015","article-title":"Cytokine profiles in bipolar affective disorder: focus on acutely ill patients","volume":"90","author":"O\u2019Brien","year":"2006","journal-title":"J Affect Disord"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.7.592","article-title":"Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder","volume":"59","author":"Rapoport","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X14666161017233642","article-title":"The role of electroconvulsive therapy (ect) in bipolar disorder: effectiveness in 522 patients with bipolar depression, mixed-state, mania and catatonic features","volume":"15","author":"Perugi","year":"2017","journal-title":"Curr Neuropharmacol"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.11.035","article-title":"Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder","volume":"131","author":"Fluitman","year":"2011","journal-title":"J Affect Disord"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1097\/00124509-200312000-00002","article-title":"Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy","volume":"19","author":"Hestad","year":"2003","journal-title":"J ECT"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e318038fce0","article-title":"Electroconvulsive therapy: a review of history, patient selection, technique, and medication management","volume":"100","author":"Taylor","year":"2007","journal-title":"South Med J"},{"key":"B258","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2015.02.029","article-title":"The impact of electroconvulsive therapy on the tryptophan\u2013kynurenine metabolic pathway","volume":"48","author":"Guloksuz","year":"2015","journal-title":"Brain Behav Immun"},{"key":"B259","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12974-016-0517-7","article-title":"Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients","volume":"13","author":"Schwieler","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B260","doi-asserted-by":"publisher","first-page":"w13880","DOI":"10.4414\/smw.2014.13880","article-title":"Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo-controlled, double-blind, randomised study","volume":"144","author":"Kargar","year":"2014","journal-title":"Swiss Med Wkly"},{"key":"B261","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/YCT.0b013e3181571abb","article-title":"Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder","volume":"24","author":"Lehtimaki","year":"2008","journal-title":"J ECT"},{"key":"B262","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/NDT.S115002","article-title":"Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial","volume":"13","author":"Husain","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"key":"B264","doi-asserted-by":"publisher","first-page":"3476240","DOI":"10.1155\/2016\/3476240","article-title":"Celecoxib adjunctive treatment to antipsychotics in schizophrenia: a review of randomized clinical add-on trials","volume":"2016","author":"Marini","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-5748(97)00029-4","article-title":"Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro","volume":"15","author":"Jarskog","year":"1997","journal-title":"Int J Dev Neurosci"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb09556.x","article-title":"Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice","volume":"840","author":"Kabiersch","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1998.6715","article-title":"Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines","volume":"149","author":"Ling","year":"1998","journal-title":"Exp Neurol"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1007\/s004410051285","article-title":"Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons","volume":"296","author":"Potter","year":"1999","journal-title":"Cell Tissue Res"},{"key":"B269","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4137\/IJTR.S16800","article-title":"Imbalanced kynurenine pathway in schizophrenia","volume":"7","author":"Kegel","year":"2014","journal-title":"Int J Tryptophan Res"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2004.08.008","article-title":"Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring","volume":"39","author":"Zuckerman","year":"2005","journal-title":"J Psychiatr Res"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbj052","article-title":"Prenatal infection as a risk factor for schizophrenia","volume":"32","author":"Brown","year":"2006","journal-title":"Schizophr Bull"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09030361","article-title":"Prenatal infection and schizophrenia: a review of epidemiologic and translational studies","volume":"167","author":"Brown","year":"2010","journal-title":"Am J Psychiatry"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.3.521","article-title":"Association of schizophrenia and autoimmune diseases: linkage of Danish national registers","volume":"163","author":"Eaton","year":"2006","journal-title":"Am J Psychiatry"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10386.x","article-title":"Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study","volume":"165","author":"Chen","year":"2011","journal-title":"Br J Dermatol"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(92)90001-L","article-title":"Schizophrenia and rheumatoid arthritis: a review","volume":"6","author":"Eaton","year":"1992","journal-title":"Schizophr Res"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(95)00073-9","article-title":"Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes","volume":"19","author":"Korschenhausen","year":"1996","journal-title":"Schizophr Res"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.066647","article-title":"Neuroinflammation in schizophrenia-related psychosis: a PET study","volume":"50","author":"Doorduin","year":"2009","journal-title":"J Nucl Med"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2009.01945.x","article-title":"Cytokines and schizophrenia: microglia hypothesis of schizophrenia","volume":"63","author":"Monji","year":"2009","journal-title":"Psychiatry Clin Neurosci"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000313","article-title":"Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106","volume":"13","author":"Takano","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.04.025","article-title":"Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study","volume":"64","author":"van Berckel","year":"2008","journal-title":"Biol Psychiatry"},{"key":"B281","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/archgenpsychiatry.2011.150","article-title":"Progressive brain changes in children and adolescents with first-episode psychosis","volume":"69","author":"Arango","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"B282","doi-asserted-by":"crossref","DOI":"10.31887\/DCNS.2006.8.1\/ldelisi","article-title":"Understanding structural brain changes in schizophrenia","volume":"8","author":"DeLisi","year":"2006","journal-title":"Dialogues Clin Neurosci"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.188.6.510","article-title":"Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies","volume":"188","author":"Steen","year":"2006","journal-title":"Br J Psychiatry"},{"key":"B284","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/mp.2014.66","article-title":"The neurobiology and treatment of first-episode schizophrenia","volume":"20","author":"Kahn","year":"2015","journal-title":"Mol Psychiatry"},{"key":"B285","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/mp.2012.199","article-title":"Markers of inflammation in the prefrontal cortex of individuals with schizophrenia","volume":"18","author":"Fillman","year":"2013","journal-title":"Mol Psychiatry"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300217","article-title":"Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype","volume":"28","author":"Garver","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.8.1316","article-title":"Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia","volume":"158","author":"Meisenzahl","year":"2001","journal-title":"Am J Psychiatry"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.05.023","article-title":"Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk","volume":"77","author":"Cannon","year":"2015","journal-title":"Biol Psychiatry"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"B290","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1586\/ern.09.144","article-title":"The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder","volume":"10","author":"Drexhage","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.7.7.789","article-title":"Inflammation and schizophrenia","volume":"7","author":"Fan","year":"2007","journal-title":"Expert Rev Neurother"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol Psychiatry"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2008.06.032","article-title":"Lipopolysaccharide-induced immune activation impairs attention but has little effect on short-term working memory","volume":"194","author":"Holden","year":"2008","journal-title":"Behav Brain Res"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2007.03.010","article-title":"Clinical evaluation of negative symptoms in schizophrenia","volume":"22","author":"Moller","year":"2007","journal-title":"Eur Psychiatry"},{"key":"B295","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cjust the facts\u201d 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr Res"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.03.022","article-title":"C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia","volume":"93","author":"Dickerson","year":"2007","journal-title":"Schizophr Res"},{"key":"B297","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2008.10.024","article-title":"Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis","volume":"176","author":"Liu","year":"2010","journal-title":"Psychiatry Res"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2008.07.017","article-title":"Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia","volume":"32","author":"Pedersen","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B299","first-page":"57","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status, symptoms, and antipsychotic effects","volume":"37","author":"Miller","year":"2011","journal-title":"Schizophr Bull"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4044-5","article-title":"Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment","volume":"233","author":"Baumeister","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.87","article-title":"C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications","volume":"21","author":"Fernandes","year":"2016","journal-title":"Mol Psychiatry"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1159\/000213565","article-title":"Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients","volume":"59","author":"Kim","year":"2009","journal-title":"Neuropsychobiology"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(00)00032-7","article-title":"Effects of antipsychotic drugs on cytokine networks","volume":"34","author":"Pollmacher","year":"2000","journal-title":"J Psychiatr Res"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.10.018","article-title":"The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia","volume":"65","author":"Song","year":"2009","journal-title":"Biol Psychiatry"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(01)00221-4","article-title":"Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study","volume":"26","author":"Cazzullo","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(97)00057-1","article-title":"In vivo immunomodulatory effects of clozapine in schizophrenia","volume":"26","author":"Maes","year":"1997","journal-title":"Schizophr Res"},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00116-4","article-title":"Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist","volume":"42","author":"Song","year":"2000","journal-title":"Schizophr Res"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2006.02.002","article-title":"Cytokines in schizophrenia and the effects of antipsychotic drugs","volume":"20","author":"Drzyzga","year":"2006","journal-title":"Brain Behav Immun"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbw221","article-title":"Kynurenic acid in schizophrenia: a systematic review and meta-analysis","volume":"43","author":"Plitman","year":"2017","journal-title":"Schizophr Bull"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-005-0432-z","article-title":"Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain","volume":"113","author":"Ceresoli-Borroni","year":"2006","journal-title":"J Neural Transm (Vienna)"},{"key":"B311","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1124\/jpet.301.2.494","article-title":"Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity","volume":"301","author":"Mirjany","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"B312","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-004-0548-4","article-title":"Clinical effects of COX-2 inhibitors on cognition in schizophrenia","volume":"255","author":"Muller","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2017.04.004","article-title":"Adjunctive celecoxib for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"92","author":"Zheng","year":"2017","journal-title":"J Psychiatr Res"},{"key":"B314","article-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013"},{"key":"B315","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.5.e472","article-title":"The genetics of autism","volume":"113","author":"Muhle","year":"2004","journal-title":"Pediatrics"},{"key":"B316","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e3283373514","article-title":"The immune system\u2019s role in the biology of autism","volume":"23","author":"Goines","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"B317","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1124\/jpet.116.234476","article-title":"Involvement of neuroinflammation during brain development in social cognitive deficits in autism spectrum disorder and schizophrenia","volume":"358","author":"Nakagawa","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"B318","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2011.08.007","article-title":"The role of immune dysfunction in the pathophysiology of autism","volume":"26","author":"Onore","year":"2012","journal-title":"Brain Behav Immun"},{"key":"B319","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fncel.2016.00021","article-title":"Astrocytes and microglia and their potential link with autism spectrum disorders","volume":"10","author":"Petrelli","year":"2016","journal-title":"Front Cell Neurosci"},{"key":"B320","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11096-0","article-title":"Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children","volume":"351","author":"Wakefield","year":"1998","journal-title":"Lancet"},{"key":"B321","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.4.e58","article-title":"No evidence for a new variant of measles-mumps-rubella-induced autism","volume":"108","author":"Fombonne","year":"2001","journal-title":"Pediatrics"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.1086\/596476","article-title":"Vaccines and autism: a tale of shifting hypotheses","volume":"48","author":"Gerber","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B323","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0264-410X(03)00532-2","article-title":"Communicating science to the public: MMR vaccine and autism","volume":"22","author":"Offit","year":"2003","journal-title":"Vaccine"},{"key":"B324","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7334.393","article-title":"Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study","volume":"324","author":"Taylor","year":"2002","journal-title":"BMJ"},{"key":"B325","doi-asserted-by":"publisher","DOI":"10.1002\/dneu.22024","article-title":"Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism","volume":"72","author":"Brown","year":"2012","journal-title":"Dev Neurobiol"},{"key":"B326","doi-asserted-by":"publisher","DOI":"10.1111\/ppe.12194","article-title":"Prenatal Infection and autism spectrum disorders in childhood: a population-based case-control study in Taiwan","volume":"29","author":"Fang","year":"2015","journal-title":"Paediatr Perinat Epidemiol"},{"key":"B327","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2016.06.005","article-title":"Maternal infection during pregnancy and risk of autism spectrum disorders: A systematic review and meta-analysis","volume":"58","author":"Jiang","year":"2016","journal-title":"Brain Behav Immun"},{"key":"B328","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024691","article-title":"Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways","volume":"6","author":"Ziats","year":"2011","journal-title":"PLoS One"},{"key":"B329","doi-asserted-by":"publisher","DOI":"10.1002\/aur.1565","article-title":"Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity","volume":"9","author":"Lim","year":"2016","journal-title":"Autism Res"},{"key":"B330","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2010.08.003","article-title":"Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome","volume":"25","author":"Ashwood","year":"2011","journal-title":"Brain Behav Immun"},{"key":"B331","doi-asserted-by":"publisher","DOI":"10.1002\/aur.42","article-title":"Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms","volume":"1","author":"Heuer","year":"2008","journal-title":"Autism Res"},{"key":"B332","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1196\/annals.1381.009","article-title":"Autoantibodies in autism spectrum disorders (ASD)","volume":"1107","author":"Wills","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"B333","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-3604","article-title":"Macrophage migration inhibitory factor and autism spectrum disorders","volume":"122","author":"Grigorenko","year":"2008","journal-title":"Pediatrics"},{"key":"B334","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2011.07.1821","article-title":"Macrophage migration inhibitory factor activates cyclooxygenase 2-prostaglandin E2 in cultured spinal microglia","volume":"71","author":"Wang","year":"2011","journal-title":"Neurosci Res"},{"key":"B335","doi-asserted-by":"publisher","DOI":"10.2174\/092986709787002745","article-title":"Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders","volume":"16","author":"Blaylock","year":"2009","journal-title":"Curr Med Chem"},{"key":"B336","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.05.024","article-title":"Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism","volume":"68","author":"Morgan","year":"2010","journal-title":"Biol Psychiatry"},{"key":"B337","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-012-1513-0","article-title":"Microglia in the cerebral cortex in autism","volume":"42","author":"Tetreault","year":"2012","journal-title":"J Autism Dev Disord"},{"key":"B338","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.20315","article-title":"Neuroglial activation and neuroinflammation in the brain of patients with autism","volume":"57","author":"Vargas","year":"2005","journal-title":"Ann Neurol"},{"key":"B339","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2014.06.006","article-title":"Inflammatory profiles in the BTBR mouse: how relevant are they to autism spectrum disorders","volume":"43","author":"Careaga","year":"2015","journal-title":"Brain Behav Immun"},{"key":"B340","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/1742-2094-9-265","article-title":"Neuroinflammation in autism spectrum disorders","volume":"9","author":"El-Ansary","year":"2012","journal-title":"J Neuroinflammation"},{"key":"B341","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1742-2094-4-3","article-title":"Effect of pioglitazone treatment on behavioral symptoms in autistic children","volume":"4","author":"Boris","year":"2007","journal-title":"J Neuroinflammation"},{"key":"B342","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0006-8993(02)02480-0","article-title":"Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2","volume":"941","author":"Kim","year":"2002","journal-title":"Brain Res"},{"key":"B343","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.58","article-title":"Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial","volume":"37","author":"Sepanjnia","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B344","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1186\/1742-2094-10-45","article-title":"Celecoxib reduces brain dopaminergic neuronal dysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide","volume":"10","author":"Kaizaki","year":"2013","journal-title":"J Neuroinflammation"},{"key":"B345","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.euroneuro.2012.08.006","article-title":"Trajectory in obsessive-compulsive disorder comorbidities","volume":"23","author":"de Mathis","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"B346","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000043","article-title":"Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder","volume":"29","author":"Heidari","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"B347","doi-asserted-by":"publisher","DOI":"10.2165\/11635850-000000000-00000","article-title":"Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Askari","year":"2012","journal-title":"CNS Drugs"},{"key":"B348","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200110000-00006","article-title":"Clinical predictors of drug response in obsessive-compulsive disorder","volume":"21","author":"Erzegovesi","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"B349","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tics.2011.11.003","article-title":"Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways","volume":"16","author":"Milad","year":"2012","journal-title":"Trends Cogn Sci"},{"key":"B350","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12297-3","article-title":"Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood","volume":"354","author":"Perlmutter","year":"1999","journal-title":"Lancet"},{"key":"B351","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2016.16020201","article-title":"Distinct subcortical volume alterations in pediatric and adult OCD: a worldwide meta- and mega-analysis","volume":"174","author":"Boedhoe","year":"2017","journal-title":"Am J Psychiatry"},{"key":"B352","doi-asserted-by":"publisher","DOI":"10.1016\/j.yhbeh.2012.03.010","article-title":"Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge","volume":"62","author":"Salazar","year":"2012","journal-title":"Horm Behav"},{"key":"B353","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2016.03.001","article-title":"Systemic inflammation induces anxiety disorder through CXCL12\/CXCR4 pathway","volume":"56","author":"Yang","year":"2016","journal-title":"Brain Behav Immun"},{"key":"B354","doi-asserted-by":"publisher","first-page":"jc8","DOI":"10.1126\/scisignal.3147jc8","article-title":"Grooming and Growing with Microglia","volume":"3","author":"Antony","year":"2010","journal-title":"Sci Signal"},{"key":"B355","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/A:1018567510105","article-title":"PK (\u2018peripheral benzodiazepine\u2019)\u2014binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia","volume":"26","author":"Banati","year":"1997","journal-title":"J Neurocytol"},{"key":"B356","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2013.06.010","article-title":"The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [(1)(1)C]PBR28 PET study","volume":"33","author":"Hannestad","year":"2013","journal-title":"Brain Behav Immun"},{"key":"B357","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(96)10049-7","article-title":"Microglia: a sensor for pathological events in the CNS","volume":"19","author":"Kreutzberg","year":"1996","journal-title":"Trends Neurosci"},{"key":"B358","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2009.205","article-title":"Evaluation of the PBR\/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia","volume":"30","author":"Martin","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"key":"B359","doi-asserted-by":"publisher","DOI":"10.1177\/0883073814543303","article-title":"Evaluation of basal ganglia and thalamic inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection and Tourette syndrome: a positron emission tomographic (PET) study using 11C-[R]-PK11195","volume":"30","author":"Kumar","year":"2015","journal-title":"J Child Neurol"},{"key":"B360","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnsys.2017.00025","article-title":"Cortico-striatal-thalamic loop circuits of the orbitofrontal cortex: promising therapeutic targets in psychiatric illness","volume":"11","author":"Fettes","year":"2017","journal-title":"Front Syst Neurosci"},{"key":"B361","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fnsys.2016.00104","article-title":"Cortico-striatal-thalamic loop circuits of the salience network: a central pathway in psychiatric disease and treatment","volume":"10","author":"Peters","year":"2016","journal-title":"Front Syst Neurosci"},{"key":"B362","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12430","article-title":"Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: a placebo-controlled, double-blind, randomized trial","volume":"70","author":"Esalatmanesh","year":"2016","journal-title":"Psychiatry Clin Neurosci"},{"key":"B363","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.22","article-title":"Are anti-inflammatory therapies viable treatments for psychiatric disorders? where the rubber meets the road","volume":"6","author":"Miller","year":"2015","journal-title":"JAMA Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00605\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T17:12:19Z","timestamp":1695143539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fpsyt.2019.00605\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":363,"alternative-id":["10.3389\/fpsyt.2019.00605"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2019.00605","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"article-number":"605"}}